LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

Home・Aktien・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Geschlossen

1.16 -3.33

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

1.15

Max

1.21

Schlüsselkennzahlen
By Trading Economics
Einkommen	3.5M -20M
EPS	-0.32
Angestellte	49
EBITDA	6.8M -22M

Empfehlungen
By TipRanks
Empfehlungen	Neutral
12-Monats-Prognose	+111.9% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	5. Aug. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	626K 75M
Vorheriger Eröffnungskurs	4.49
Vorheriger Schlusskurs	1.16

Pliant Therapeutics Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

1. Juni 2026, 23:48 UTC

Market Talk

Nikkei May Rise on Optimism Over AI Demand -- Market Talk

1. Juni 2026, 23:38 UTC

Akquisitionen, Fusionen, Übernahmen

Google Seeks $80 Billion for AI Buildout; Berkshire Will Buy $10 Billion Stake -- WSJ

1. Juni 2026, 23:37 UTC

Market Talk

Oil Edges Higher; Trump Seeks to Quell Israel-Hezbollah Conflict -- Market Talk

1. Juni 2026, 23:01 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

1. Juni 2026, 23:01 UTC

Market Talk

Dexus Stuck in 'Too Hard' Basket -- Market Talk

1. Juni 2026, 22:08 UTC

Akquisitionen, Fusionen, Übernahmen

Alphabet to Issue $80 Billion of Equity for AI Buildout. Berkshire to Buy $10 Billion. -- Barrons.com

1. Juni 2026, 22:01 UTC

Akquisitionen, Fusionen, Übernahmen

Alphabet to Issue $80 Billion of Equity for AI Buildout. Berkshire to Buy $10 Billion. -- Barrons.com

1. Juni 2026, 22:01 UTC

Akquisitionen, Fusionen, Übernahmen

Google Seeks to Raise $80 Billion for AI Infrastructure -- Update

1. Juni 2026, 21:55 UTC

Akquisitionen, Fusionen, Übernahmen

Greg Abel's Week Is Off to Quite a Start -- WSJ

1. Juni 2026, 21:53 UTC

Market Talk

Strong Earnings Suppress Concerns About Oil Market -- Market Talk

1. Juni 2026, 21:22 UTC

Market Talk

Akquisitionen, Fusionen, Übernahmen

Berkshire's Abel Takes Big Swing With Back-to-Back Deals -- Market Talk

1. Juni 2026, 20:50 UTC

Market Talk

Akquisitionen, Fusionen, Übernahmen

Tech, Media & Telecom Roundup: Market Talk

1. Juni 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

1. Juni 2026, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

1. Juni 2026, 20:46 UTC

Akquisitionen, Fusionen, Übernahmen

The Odds SpaceX Merges With Tesla Are Higher Than You Think -- Barrons.com

1. Juni 2026, 20:22 UTC

Akquisitionen, Fusionen, Übernahmen

Array Digital Infrastructure Doesn't Expect Additional Divs in 2026

1. Juni 2026, 20:21 UTC

Akquisitionen, Fusionen, Übernahmen

Array Digital Infrastructure Div Payable June 25 to Hldrs of Record June 11

1. Juni 2026, 20:21 UTC

Akquisitionen, Fusionen, Übernahmen

Array Digital Infrastructure Declares $11 Special Div

1. Juni 2026, 20:20 UTC

Akquisitionen, Fusionen, Übernahmen

Array Completes Sale of Select Spectrum Assets to Verizon for $1B

1. Juni 2026, 19:40 UTC

Market Talk

Remittances to Mexico Rise for Third Straight Month -- Market Talk

1. Juni 2026, 19:28 UTC

Market Talk

BoC Official Reiterates Need to Improve Business Investment -- Market Talk

1. Juni 2026, 19:01 UTC

Market Talk

Oil Futures Rise On Concerns About U.S.-Iran Talks -- Market Talk

1. Juni 2026, 18:58 UTC

Market Talk

U.S. Natural Gas Futures Snap 3-Session Winning Streak -- Market Talk

1. Juni 2026, 18:54 UTC

Akquisitionen, Fusionen, Übernahmen

Berkshire Stock Drops. Its Bargain-Priced Deal for Home Builder Fails to Impress Investors. -- Barrons.com

1. Juni 2026, 18:33 UTC

Market Talk

Mexican PMIs Show Sluggish Manufacturing in May -- Market Talk

1. Juni 2026, 18:32 UTC

Market Talk

Precious Metals Fall to Start June -- Market Talk

1. Juni 2026, 18:00 UTC

Akquisitionen, Fusionen, Übernahmen

Marsh McLennan Agency Completes Acquisition Of TriBridge Partners >MRSH

1. Juni 2026, 17:18 UTC

Market Talk

Global Asset Managers Accumulate Canadian Government Debt -- Market Talk

1. Juni 2026, 17:18 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

1. Juni 2026, 17:10 UTC

Market Talk

Akquisitionen, Fusionen, Übernahmen

Salesforce Estimated to Get $225M Sales Boost From Contentful -- Market Talk

Peer-Vergleich

Kursveränderung

Pliant Therapeutics Inc Prognose

Kursziel

By TipRanks

111.9% Vorteil

12-Monats-Prognose

Durchschnitt 2.67 USD 111.9%

Hoch 3 USD

Tief 2 USD

Basierend auf 5 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Pliant Therapeutics Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Neutral

5 ratings

Buy

Halten

Sell

Basierend auf 5 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Pliant Therapeutics Inc – Dist abgegeben haben.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.